Kailera Therapeutics, Inc. (KLRA)

NASDAQ: KLRA · Real-Time Price · USD

16.64

-0.41 (-2.40%)

Jul 31, 2026, 12:15 PM EDT - Market open

Kailera Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
Selling, General & Admin	49.23
Research & Development	109.11
Total Operating Expenses	158.34
Operating Income	-158.34
Interest Income	11.05
Other Non-Operating Income (Expense)	-1.66
Total Non-Operating Income (Expense)	9.39
Pretax Income	-148.96
Net Income	-148.96
Net Income to Common	-148.96
Net Income Growth	-
Shares Outstanding (Basic)	0
Shares Outstanding (Diluted)	0
Shares Change	-
EPS (Basic)	-949.00
EPS (Diluted)	-949.00
EPS Growth	-

Additional Metrics

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
Free Cash Flow	-122.3
Free Cash Flow Growth	-
Free Cash Flow Per Share	-778968.00
EBITDA	-158.03
EBIT	-158.34

SEC Filings: 10-K · 10-Q